GLP-1s, the new blockbuster drug class, has taken off in popularity as a powerful treatment for patients with obesity and Type 2 diabetes, but they’ve driven an drastic increase in plastic surgery procedures, too, Bloomberg reported June 25.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
